“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
By Ruma Paul
DHAKA, 13 October (Reuters) – Bangladesh will co-finance a complex national trial of a possible coronavirus vaccine developed through China’s Sinovac Biotech, country’s fitness minister Zahid Maleque told Reuters on Tuesday.
His comments came weeks after Sinovac asked the Bangladeshi to co-finance national trials, which according to the resources would charge about $7 million.
Sinovac informed the Health Ministry in a letter, notified via Reuters, that a delay in approvals in Bangladesh had led to a reallocation of the budget for country trials.
“We’re not co-financing the rehearsal. It’s not in the agreement. They never asked for cash when they contacted us,” Maleque said.
“According to the agreement, they will doseize all the prices of the trial, give us 110,000 loose vaccines and percentage the generation so that our pharmaceutical corporations can manufacture the vaccine. “
Sinovac, which last month initiated phase III trials of its “CoronaVac” vaccine in Turkey, did not respond without delay to a request for comment.
In the September letter to the government, Sinovac also said that he had implemented investment for the Coalition for Innovations in Epidemic Preparedness (CEPI) trial, a base subsidized through public budget and personal philanthropy, but had been successful.
“We are implementing plans to partially rectify the investment scenario until late October or early November,” the company said in the letter, although it would still require co-financing to complete the test in Bangladesh.
The country’s national medical firm gave the green light to the phase III trial in July, and government approval came a month later.
Maleque said Sinovac is still on the loose to make the trial in Bangladesh with his own funds.
“You can take the test. But we can’t co-finance the test with a personal company. It will have to be a government-to-government agreement if we opt for co-financing,” he added.
The minister said Bangladesh was in talks with at least five vaccine pioneers, Astrazeneca added.
Bangladesh reported 22 deaths and 1,537 new COVID-19 infections on Tuesday, bringing the total number of reported cases in the country to 381275 and the death toll to 5577.
“We will ensure the vaccine for our population. We’ve allocated a budget for this and our progression partners are also eager to fund us,” Maleque said.
(Report through Ruma Paul; Edited through Euan Rocha and Gareth Jones)